Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ensifentrine - Verona Pharma

Drug Profile

Ensifentrine - Verona Pharma

Alternative Names: RPL 554

Latest Information Update: 16 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vernalis
  • Developer Verona Pharma
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Imines; Isoquinolines; Small molecules; Urea compounds
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Allergic rhinitis; Asthma; Asthma

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis
  • Discontinued Allergic rhinitis

Most Recent Events

  • 14 Jan 2019 Safey and efficacy data from a phase III trial in Chronic obstructive pulmonary disease released by Verona Pharma
  • 17 Dec 2018 Verona Pharma plan a clinical trial for dry powder inhaler (DPI) formulations of ensifentrine for Chronic obstructive pulmonary disease in December 2018
  • 17 Dec 2018 Phase-II clinical trials in Chronic obstructive pulmonary disease in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top